Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E PIK3CA E542K |
Therapy | Dasatinib + Trametinib |
Indication/Tumor Type | anaplastic thyroid carcinoma |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E PIK3CA E542K | anaplastic thyroid carcinoma | resistant | Dasatinib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, an anaplastic thyroid cancer cell line harboring BRAF V600E and PIK3CA E542K was resistant to the combination of Sprycel (dasatinib) and Mekinist (trametinib) in culture (PMID: 37713162). | 37713162 |
PubMed Id | Reference Title | Details |
---|---|---|
(37713162) | AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition. | Full reference... |